Off-Label Uses for Lisinopril

Primary Off-Label Uses with Strong Evidence

• The American College of Cardiology recommends monitoring serum creatinine and potassium within 2-4 weeks of initiation or dose increase, particularly in patients with chronic kidney disease 1
• The American Heart Association suggests that ACE inhibitors, including lisinopril, reduce post-MI remodeling and improve outcomes in patients with left ventricular dysfunction, with particular benefit in hypertensive patients 2, 1

Secondary Off-Label Uses with Emerging Evidence

• The American College of Cardiology indicates that ACE inhibitors, including lisinopril, have demonstrated reduction in onset of new diabetes mellitus in patients with cardiovascular complications 2

Critical Dosing Considerations for Off-Label Uses

• The European Society of Cardiology recommends dose adjustment when creatinine clearance <30 mL/min 3
• The American College of Cardiology suggests starting at lower doses (2.5-5 mg) in patients with baseline renal impairment and titrating based on tolerance 4

Important Safety Considerations and Monitoring

• The American College of Cardiology states that absolute contraindications for lisinopril include pregnancy, history of angioedema with ACE inhibitors, and bilateral renal artery stenosis 4, 1
• The American Heart Association recommends checking blood pressure, serum creatinine, and potassium within 2-4 weeks of initiation or dose increase 1
• The European Society of Cardiology suggests accepting up to 10-20% increase in serum creatinine as expected pharmacodynamic effect, not necessarily indicating harm 5

Clinical Pitfalls to Avoid

• The American College of Cardiology advises against discontinuing lisinopril prematurely for mild creatinine elevation (10-20% increase), as this represents the intended renoprotective mechanism 5, 1
• The European Society of Cardiology recommends avoiding initiation of lisinopril in patients at immediate risk of cardiogenic shock; stabilize first with other therapies 4
• The American Heart Association suggests not combining ACE inhibitors with ARBs in patients with LVEF <40%, as this increases adverse effects without additional mortality benefit; use mineralocorticoid receptor antagonist instead 6